Sugary taste with zero calories sounds delicious to investors.
News & Analysis: Amyris
These companies led the markets higher.
A bullish article is pushing shares higher, but investors need to remain grounded.
A more effective way of delivering CBD could unlock significant growth opportunities for this unknown small-cap.
Investors are less than two years removed from a significant accounting discrepancy. A closer look at SEC filings reveals another potential cause for concern.
Investors were pleased by relatively positive operating results in the first quarter of 2020. Can the synthetic biology company turn those results into a durable trend?
The company might have mobilized to respond to the coronavirus pandemic, but investors must focus on whether that results in tangible business progress.
The business needs to provide GAAP revenue and GAAP product gross margin for its consumer brands to reassure nervous investors.
Can the industrial biotech amend its manufacturing agreement to lower expenses? Will it matter?
Another year, another set of financing transactions that provide a lifeline to the struggling company.